Maria J. Garrido
Pamplona, NC, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 34 publications
Monomethyl-auristatin E-based anti-CD137 (4-1BB) antibody drug conjugates are not suitable tools to deplete activated T lymphocytes.
Journal: Immunobiology
Published: October 27, 2025
Azobenzene-bridged ionizable amphiphilic Janus glycosides for light-controlled, single-component and organ-modulable pDNA delivery.
Journal: Communications chemistry
Published: October 24, 2025
Emerging nanoparticle-based therapies for pancreatic cancer: Current clinical landscape.
Journal: Advanced drug delivery reviews
Published: July 24, 2025
Liposomal encapsulation of cholecalciferol mitigates in vivo toxicity and delays tumor growth.
Journal: Frontiers in immunology
Published: November 15, 2024
Quantitative Approach to Explore Regulatory T Cell Activity in Immuno-Oncology.
Journal: Pharmaceutics
Published: October 01, 2024
Intraperitoneal administration of mRNA encoding interleukin-12 for immunotherapy in peritoneal carcinomatosis.
Journal: Journal of nanobiotechnology
Published: July 29, 2024
β-Cyclodextrin-based geometrically frustrated amphiphiles as one-component, cell-specific and organ-specific nucleic acid delivery systems.
Journal: Carbohydrate polymers
Published: July 03, 2024
Lipid-based nanosystems: the next generation of cancer immune therapy.
Journal: Journal of hematology & oncology
Published: May 23, 2024
Foxp3 inhibitory peptide encapsulated in a novel CD25-targeted nanoliposome promotes efficient tumor regression in mice.
Journal: Acta pharmacologica Sinica
Published: January 09, 2024
Assessment of Clinical Response to V937 Oncolytic Virus After Intravenous or Intratumoral Administration Using Physiologically-Based Modeling.
Journal: Clinical pharmacology and therapeutics
Published: January 20, 2023
Stealth nanoparticles in oncology: Facing the PEG dilemma.
Journal: Journal of controlled release : official journal of the Controlled Release Society
Published: May 25, 2022
Recombinant porphobilinogen deaminase targeted to the liver corrects enzymopenia in a mouse model of acute intermittent porphyria.
Journal: Science translational medicine
Published: January 12, 2022
Last Updated: 09/26/2026